RNAi-based therapeutic strategies for metabolic disease. - Wikidata - awgldk - TriplyDB

RNAi-based therapeutic strategies for metabolic disease.

RNAi-based therapeutic strategies for metabolic disease.

http://www.wikidata.org/entity/Q37866632

about

Control of macrophage metabolism and activation by mTOR and Akt signaling Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules Post-transcriptional regulation in metabolic diseases Liver-targeted gene therapy: Approaches and challenges The Biochemical Cascades of the Human Pancreatic β-Cells: The Role of MicroRNAs.High-density lipoproteins for the systemic delivery of short interfering RNA.Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle Role of MicroRNAs in Hepatocellular Carcinoma Using functional genomics to overcome therapeutic resistance in hematological malignancies.A simplified and versatile system for the simultaneous expression of multiple siRNAs in mammalian cells using Gibson DNA Assembly Screening nylon-3 polymers, a new class of cationic amphiphiles, for siRNA delivery.In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice Evidence for an interaction of neuronostatin with the orphan G protein-coupled receptor, GPR107.Managing diabetes with nanomedicine: challenges and opportunities An in silico approach to design potential siRNA molecules for ICP22 (US1) gene silencing of different strains of human herpes simplex 1.Progress in microRNA delivery.Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants.Peptide- and Amine-Modified Glucan Particles for the Delivery of Therapeutic siRNA.MicroRNA silencing and the development of novel therapies for liver disease.In vivo gene delivery by nonviral vectors: overcoming hurdles?Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors.Comprehensive overview and assessment of computational prediction of microRNA targets in animals.SMMRNA: a database of small molecule modulators of RNA.MicroRNAs in hepatic pathophysiology in diabetes.Selective nuclear localization of siRNA by metallic versus semiconducting single wall carbon nanotubes in keratinocytes.Gold-installed biostable nanocomplexes for tumor-targeted siRNA delivery in vivo.Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.Double Stranded RNA in Human Seminal Plasma.Short versus long double-stranded RNA activation of a post-transcriptional gene knockdown pathway.Nanomaterials for the Local and Targeted Delivery of Osteoarthritis Drugs

P2860

Q26781587-803D1B61-E9E8-47DB-84B3-AEB9B9633002 Q26997097-B04A0C1C-5574-4FBF-9992-72489D606CAE Q27028039-750BB2B3-8B59-438E-8151-0394B014FA8C Q28085748-B060E504-D73A-4DC0-936A-BABAC80BDA61 Q33664707-6846FD28-2B8B-4350-A03D-BA048BC086EA Q33786171-778D9F86-7508-4F18-848B-157191B97E3D Q33935474-2CEAF2B8-281A-4B46-A553-1DA7DDE0D079 Q34052685-B231D3B8-DBAE-4A02-B73B-DA6EF43F51CC Q34348824-D9696893-5150-4485-984F-9F6F5ECA5C80 Q34401328-89BC5E29-75B8-4095-93E7-A3AD42875C74 Q34514698-FA928D02-494C-4197-978B-9BD42EB2A03A Q35057561-28D07A67-E105-4333-B10B-652981B23D41 Q36298651-C761C41F-AEFE-43A5-93CD-90232F609298 Q36454494-489AB443-E32D-411F-A363-0C63F6788BE8 Q36574654-9AA6A7B1-5D71-4D4E-80D0-311CE5DA7AC5 Q37134388-2A71D95C-FC97-46E0-915B-FDB6AF830695 Q37478933-F1E291B7-7968-4425-85DA-3EC22CE37049 Q37481839-ABD11EB8-7F17-4EA1-ABC6-DCD705CDE00C Q37498037-F697170B-896C-49CC-9A2D-B67BA7C3D5DF Q38002726-3C5D0A01-B4DF-43A7-877E-D71679794BF3 Q38004708-AEC83F26-1644-4379-92BE-3C00074711DA Q38148788-EC0D6D53-93F7-4638-83BB-BCB0EFBE1E6F Q38282622-A3901196-552E-4854-B0B9-DEAFFF4B6DF7 Q38491740-1A7BF991-7899-4D67-B4B9-AFD87F5FB047 Q38751634-5F800BDF-6FAA-4391-8FF5-D35B19AC2009 Q38776971-DCA94153-7D41-4D23-8100-B854340CEE9C Q38831061-6128C751-3F69-43C9-A7D9-226390F56EFF Q42367659-A058AF2E-1090-4944-95FE-1A9C38BF2BAC Q46270483-6C989CFD-FF48-4A2A-A74A-3FD29078330F Q52541942-434C0260-170D-4A53-81CE-7F664B4A59DA Q58910462-53D13579-EC3A-492B-BF5C-5BB9DDC92066

P2860

RNAi-based therapeutic strategies for metabolic disease.

http://www.wikidata.org/entity/Q37866632

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

RNAi-based therapeutic strategies for metabolic disease.

@en

RNAi-based therapeutic strategies for metabolic disease.

@nl

type

label

RNAi-based therapeutic strategies for metabolic disease.

@en

RNAi-based therapeutic strategies for metabolic disease.

@nl

prefLabel

RNAi-based therapeutic strategies for metabolic disease.

@en

RNAi-based therapeutic strategies for metabolic disease.

@nl

P1433

Q37866632-FBC0EA09-3312-4EC8-A982-6B6FA9EBE4CC

P1476

Q37866632-81E934EB-066C-4569-A5F0-D4F9D32B3554

P2093

Q37866632-842F3C52-E2C8-43E8-B856-DCCEEBC4090A

Q37866632-AC5565B0-7477-45C4-9CD0-D8393C72BCC6

Q37866632-C101CF68-4867-49BF-B1C7-DB4EF3E9FAAD

P2860

Q37866632-00912358-3003-4006-A213-14F70F247526

Q37866632-00AC48AD-F77A-49AE-9CFB-5CC8C71F9D6B

Q37866632-00DE1E8B-840E-4318-8084-BA78B1E7CB0E

Q37866632-0135A2C5-3A91-4C44-8B8A-A0CB2118C378

Q37866632-03F6032A-EE46-4974-B281-F6B76D60FB1D

Q37866632-0635CE55-CBB2-4E3E-AD46-4E7F113184C1

Q37866632-06742002-A096-4895-AD10-36FF13784351

Q37866632-06D4E81A-8FEC-4ADB-ADE4-3EBFC4850AE0

Q37866632-07494829-4AEC-4A43-813B-EBE46FDCF9A5

Q37866632-08E43EDE-46E9-4066-8BEF-39A8E0DDFC30

P2888

Q37866632-77861096-9D7F-4670-B537-E2B05C26C56A

P304

Q37866632-D9BD1F52-B6E9-4E15-91A6-2448874CAA43

P31

Q37866632-94F6C527-6012-4281-80FF-EBC0D2E3A6A7

P356

Q37866632-8092A7C6-7FD2-482F-A319-63E759B82383

P433

Q37866632-B954A123-FBCB-436F-A9AB-1CCB73933D51

P478

Q37866632-066F3721-D045-4A87-B20D-155EE4A526A4

P577

Q37866632-C1857ADE-953A-443B-972A-801C0CDA2B96

P698

Q37866632-EB880850-54A6-4F07-BE5F-D5D0738E3C11

P356

P1433

Nature Reviews Endocrinology

P1476

RNAi-based therapeutic strategies for metabolic disease.

@en

P2093

Gregory J Tesz

http://www.w3.org/2001/XMLSchema#string

Michael P Czech

http://www.w3.org/2001/XMLSchema#string

Myriam Aouadi

http://www.w3.org/2001/XMLSchema#string

P2860

Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

microRNAs and cholesterol metabolism

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Small silencing RNAs: an expanding universe

The promises and pitfalls of RNA-interference-based therapeutics

Molecular biology of PCSK9: its role in LDL metabolism

Targeted Delivery of Small Interfering RNA to Human Dendritic Cells To Suppress Dengue Virus Infection and Associated Proinflammatory Cytokine Production

P2888

P304

473-484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRENDO.2011.57

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21502982

http://www.w3.org/2001/XMLSchema#string